抗 CD22/CD19 CAR-T 细胞疗法 CAR-T2219.1 在成人和儿童复发/难治性 B-ALL 中的 I/II 期试验
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.
99.3分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Wilms 瘤 1 肽负载树突状细胞疫苗治疗复发/难治性急性白血病患者
英文原题：Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.
查看英文原题
Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
这些结果表明，基于 DC 的免疫疗法对急性白血病患者是安全且可行的。
研究思路结论见上方概要
背景
复发性或难治性急性白血病患者的预后较差。在本初步研究中，我们用负载Wilms瘤1（WT1）肽的树突状细胞（DCs）治疗复发性或难治性急性白血病患者，并检查了安全性、临床和免疫学反应。
方法
共入组11例符合条件的患者。DC每2-3周给药一次，并辅以OK-432佐剂。
结果
治疗耐受良好。在四名患者中观察到白血病细胞减少或WT1 mRNA表达降低，并维持了相当长的时间。所有有反应的患者均表现出针对WT1的免疫反应，这可能与临床结局相关。接种疫苗后观察到调节性T细胞绝对数量减少，表明DC疫苗可能有助于逆转免疫抑制。
展开英文摘要原文
METHODS
Eleven eligible patients were enrolled. DCs were administered every 2-3 weeks with OK-432 adjuvant.
RESULTS
The treatment was well tolerated. The reduction of leukemia cells or the expression of WT1 mRNA was observed in four patients which was maintained for a significant period of time. All the responding patients manifested immune responses against WT1 which might be related to clinical outcome. Decreases in the absolute number of regulatory T cells were observed following vaccination, indicating that DC vaccinations may contribute to the reversal of immunosuppression.
CONCLUSION
These results indicate that DC-based immunotherapy is safe and feasible for patients with acute leukemia.
论文信息
- 作者
- Ogasawara M、Miyashita M、Yamagishi Y、Ota S
- 单位
- Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.Japan
- 期刊
- Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2022 Jun
- 原文标识
- PubMed 35249263 · DOI 10.1111/1744-9987.13828